16.72 USD
↘ 0.58 (3.33%)LIVE (AS OF 11:59 AM EDT)
Bicara Therapeutics Inc. Common Stock
BCAXNASDAQ • USD
Market: OPEN
Bicara Therapeutics Inc. Common Stock (BCAX) is currently trading at $16.72. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest BCAX is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Oct 5, 2026.
Open?$17.43
High?$17.49
Low?$16.51
Prev. Close?$17.29
Volume?270.6K
Avg. Volume?617.9K
VWAP?$16.80
Rel. Volume?0.44x
Bid / Ask
Bid?$16.73 × 100
Ask?$16.83 × 100
Spread?$0.10
Midpoint?$16.78
Valuation & Ratios
Market Cap?1.1B
Shares Out?66.2M
Float?50.7M
Float %?77.2%
P/E Ratio?N/A
P/B Ratio?2.44
EPS?-$2.80
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Themes
Address
116 HUNTINGTON AVENUE SUITE 703
BOSTON, MA 02116
Phone: 617-468-4219
BOSTON, MA 02116
Phone: 617-468-4219
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?39
Piotroski F-Score?0/9Weak
Altman Z-Score?14.28Safe
Confidence?41%Low
Short InterestSqueeze Risk
Short % of Float?22.06%Squeeze Risk
Short Interest?11.2M
Days to Cover?22.6
Free Float50.7M
Avg Daily Volume496.0K
Settlement Date2026-09-15
Financial Health
Current Ratio?11.59Strong
Quick Ratio?11.59Strong
Cash Ratio?2.22Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.44CHEAP▾
Peers100
S&P65
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-5.2CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-39.5%WEAK▾
S&P3
ROA?-36.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-135248000
Enterprise Value?$1.0B
Fundamentals ratios updated end of day